Replies to post #529 on KemPharm Inc. (KMPH)

[pzottkpz]

I fully agree with you

I have stated multiple times that this is a repurposing drug company that gets paid through royalties, while showing there are so many other choices and the investment world doesn’t give a crap about another drug in this space

the executives have exorbitant salaries plus options for a penny stock company that needed to do a reverse split to get on a bigger exchange which was a poor move but shows they are so involved with the stock price that money is the only thing that matters. The repurposing of those reverse split shares proves that point. The average shareholder doesn’t matter here

From the looks of it there are 35-40MM shares fully diluted at the very minimum plus the bondholders that may not be involved in that stock calculation, which can grow exponentially. At the minimum it’s already a “double” in the stock price as it is double the amount of shares from the offering, but there will be more.

Using the minimum calculations, a run to 20 is equivalent to a run to 40. That’s unrealistic.
There will not be a buyout, but there will be special wording to make one think it’s possible.

Add in the stampede sell before or on the actual news
Add in the overall recent market, possible margin calls, etc. Is this really a choice for an investment?
....and what if they delay, don’t get the label they’re hoping for, or the almighty CRL —-LOOK OUT BELOW

[MiamiGent]

KMPH

Just to be clear, I am only disputing the short covering potential for this stock. I have no problem with the science or market potential of the drug. JUST TO BE CLEAR, AS THE LEADING POSTER ABOUT THIS STOCK WITH 152 POSTS ON THIS BOARD AND ONE OF THE VERY FEW KMPH PROPONENTS HERE, I HAVE N E V E R SPOKEN OF SHORT COVERING POTENTIAL OF THIS STOCK.

I AM PLEASED YOU HAVE NO PROBLEM WITH THE SCIENCE OF THIS DRUG CANDIDATE

I AM PLEASED YOU HAVE NO PROBLEM WITH THE MARKET POTENTIAL OF THIS STOCK


People should be aware, however, that KMPH has already sold the rights to the drug to a private company. KMPH will be entitled to royalties and milestone payments along the way, but we don't have a lot of definition (other than the total) of the milestone payments or their timing. PEOPLE SHOULD BE AWARE THE PRIVATE COMPANY, GPC WILL PAY FOR ALL THE COSTS TO BRING KP415 TO MARKET, SHOULD IT BE APPROVED THIS COMING TUESDAY. MILESTONE PAYMENTS GO AS HIGH AS $493 MILLION DOLLARS PLUS UP TO 20% ROYALTIES ON SALES BEFORE EXPENSES. THIS IS A VERY GOOD DEAL FOR KEMPHARM, REFLECTING THE PROMISE OF ITS CANDIDATE. THE PARTNER KMPH HAS ENTRUSTED TO BRING KP415 TO MARKET ARE FORMER SHIRE PHARMA PEOPLE WHO BROUGHT THE PRESENT LEADING ATTENTION DEFIFICIT DISORDER DRUG TO MARKET. AN OUTSTANDING PARTNER! no longer has control of the development, manufacturing, or marketing of the drug. THIS IS HOW DRUG MANUFACTURERS TYPICALLY BRING DRUGS TO MARKET- THEY SELL THE RIGHTS, THERE IS NOTHING AT ALL NEGATIVE ABOUT THIS. KENFARM STILL KP415 HAS ROW (FOREIGN) RIGHTS TO SELL, HUGE FURTHER POTENTIAL The bulk of the profits will be earned by Gurnet Point Capital and its subsidiary Corium International. SINCE WHEN IS $493 MILLION DOLLARS PLUS 20% OF THE SALES BEFORE EXPENSES CHOPPED LIVER? The royalty/milestone payments may well make KMPH a winner in the future. WITH KP415 APPROVAL, KENFARM'S PROPRIETARY PLATFORM WILL BE VALIDATED AND IT CAN PROCEED TO USE SAME TECHNOLOGY TO A PLETHERA OF ALREADY APPROVED DRUGS. ITS PLATFORM IS HIGHLY SCALABLE. It's just hard to value it at the moment (for me).

MG IN CAPS